Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

Cited In for PubMed (Select 15194770)

1.

Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.

Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA.

J Virol. 2014 Dec;88(23):13769-80. doi: 10.1128/JVI.02232-14. Epub 2014 Sep 17.

2.

Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses.

Hoffmann M, Müller MA, Drexler JF, Glende J, Erdt M, Gützkow T, Losemann C, Binger T, Deng H, Schwegmann-Weßels C, Esser KH, Drosten C, Herrler G.

PLoS One. 2013 Aug 30;8(8):e72942. doi: 10.1371/journal.pone.0072942. eCollection 2013.

3.

Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.

Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R.

Viral Immunol. 2013 Apr;26(2):126-32. doi: 10.1089/vim.2012.0076.

4.

Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.

Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS.

PLoS One. 2012;7(11):e50366. doi: 10.1371/journal.pone.0050366. Epub 2012 Nov 21.

5.

Mechanisms of coronavirus cell entry mediated by the viral spike protein.

Belouzard S, Millet JK, Licitra BN, Whittaker GR.

Viruses. 2012 Jun;4(6):1011-33. doi: 10.3390/v4061011. Epub 2012 Jun 20. Review.

6.

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Coughlin MM, Prabhakar BS.

Rev Med Virol. 2012 Jan;22(1):2-17. doi: 10.1002/rmv.706. Epub 2011 Sep 8. Review.

7.

Simultaneous detection of antibodies to mouse hepatitis virus recombinant structural proteins by a microsphere-based multiplex fluorescence immunoassay.

Kunita S, Kato K, Ishida M, Hagiwara K, Kameda S, Ishida T, Takakura A, Goto K, Sugiyama F, Yagami K.

Clin Vaccine Immunol. 2011 May;18(5):758-66. doi: 10.1128/CVI.00467-10. Epub 2011 Mar 23.

8.

Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein.

Reguera J, Ordoño D, Santiago C, Enjuanes L, Casasnovas JM.

J Gen Virol. 2011 May;92(Pt 5):1117-26. doi: 10.1099/vir.0.027607-0. Epub 2011 Jan 12.

9.

SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion.

Madu IG, Belouzard S, Whittaker GR.

Virology. 2009 Oct 25;393(2):265-71. doi: 10.1016/j.virol.2009.07.038. Epub 2009 Aug 29.

10.

Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide.

Madu IG, Roth SL, Belouzard S, Whittaker GR.

J Virol. 2009 Aug;83(15):7411-21. doi: 10.1128/JVI.00079-09. Epub 2009 May 13.

11.

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS.

Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755 . Review. Erratum in: Expert Opin Biol Ther. 2009 Apr;9(4):533.

12.

Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin.

Ren W, Qu X, Li W, Han Z, Yu M, Zhou P, Zhang SY, Wang LF, Deng H, Shi Z.

J Virol. 2008 Feb;82(4):1899-907. Epub 2007 Dec 12.

13.

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.

Cheng VC, Lau SK, Woo PC, Yuen KY.

Clin Microbiol Rev. 2007 Oct;20(4):660-94. Review.

14.
15.

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.

DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A.

Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93. Epub 2007 May 29.

16.

Animal models and vaccines for SARS-CoV infection.

Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K.

Virus Res. 2008 Apr;133(1):20-32. Epub 2007 May 11.

17.

Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.

Hu H, Lu X, Tao L, Bai B, Zhang Z, Chen Y, Zheng F, Chen J, Chen Z, Wang H.

Clin Vaccine Immunol. 2007 Jul;14(7):894-901. Epub 2007 May 9.

18.

Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.

Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R.

Virus Res. 2008 Apr;133(1):45-62. Epub 2007 Apr 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk